Jacobs Levy Equity Management, Inc Alnylam Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 410,342 shares of ALNY stock, worth $184 Million. This represents 0.78% of its overall portfolio holdings.
Number of Shares
410,342
Previous 17,674
2221.73%
Holding current value
$184 Million
Previous $5.76 Million
3146.83%
% of portfolio
0.78%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding ALNY
# of Institutions
915Shares Held
115MCall Options Held
1.26MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...